DAX-1,58 % EUR/USD+0,03 % Gold+0,09 % Öl (Brent)+0,73 %

Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy

Nachrichtenquelle: GlobeNewswire
23.04.2019, 07:00  |  404   |   |   

F. Hoffmann-La Roche Ltd / Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

  • Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.1 About 15 to 20 percent of women diagnosed with breast cancer are HER2 positive.2
  • The VENTANA HER2 Dual ISH DNA Probe Cocktail assay3 aids in identifying breast and gastric cancer patients eligible for the targeted Roche drug Herceptin (trastuzumab), providing fast results with widely available laboratory instruments. 
  • This approval supports Roche's personalized healthcare strategy to provide treatment to patients who can benefit most from a specific medicine.

Basel, 23 April 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer. HER2 - human epidermal growth factor receptor 2 - is an important biomarker found in breast and gastric cancers.4 Its detection and inhibition can help to more effectively manage these aggressive cancers.

The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to be completed within the same day, providing clinicians the ability to get results back quicker than the most common methods of confirmatory testing for HER2. Results can be read using light microscopy, eliminating the need for a specialized fluorescence microscope. 

"The new VENTANA HER2 Dual ISH assay advances Roche's commitment to personalized healthcare by delivering critical information on treatment options for breast and gastric cancer patients faster," said Michael Heuer, CEO Roche Diagnostics. "Quick results are crucial in the fight against cancer, and every additional day that a clinician and a patient must wait for test results is a day too long."

This assay is currently being launched in Europe, the Middle East and Africa, as well as Latin America and Asia Pacific. It will be submitted to the U.S. Food and Drug Administration for approval.

For more information about the assay, please visit the Roche Tissue Diagnostics breast cancer IHC/ISH portfolio page or the Anatomic Pathology site.

Seite 1 von 3
Wertpapier
Roche Holding


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
16.05.19
16.05.19
14.05.19
14.05.19
10.05.19
08.05.19
08.05.19
07.05.19
06.05.19
29.04.19